- Report
- February 2025
- 200 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Drug Pipelines
- June 2020
- 48 Pages
Global
From €1896EUR$2,000USD£1,584GBP
- Report
- July 2023
- 110 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- August 2023
- 84 Pages
Global
From €3500EUR$3,956USD£3,026GBP
- Report
- December 2022
- 44 Pages
Global
From €1896EUR$2,000USD£1,584GBP
- Report
- October 2022
- 210 Pages
Global
From €3384EUR$3,570USD£2,827GBP
Toxoplasmosis is an infectious disease caused by the parasite Toxoplasma gondii. It is a major cause of morbidity and mortality in immunocompromised individuals, such as those with HIV/AIDS, and can cause severe birth defects in pregnant women. Treatment of toxoplasmosis is typically done with a combination of drugs, including sulfonamides, pyrimethamine, and clindamycin.
The toxoplasmosis drug market is a subset of the larger infectious diseases drug market. It is composed of a variety of drugs used to treat and prevent toxoplasmosis, including sulfonamides, pyrimethamine, and clindamycin. These drugs are used in combination to treat the infection, and are often prescribed in combination with other drugs to prevent the development of drug resistance.
Some companies in the toxoplasmosis drug market include GlaxoSmithKline, Merck, Pfizer, Sanofi, and Novartis. Show Less Read more